咨询电话：15012456311
咨询电话：15012456311奥格列汀市场前景：奥格列汀为超长效二肽基肽酶-4(DPP-4)抑制剂，其作用机制是通过抑制体内DPP-4酶对胰高血糖素样肽-1（GLP-1）的降解作用，延长GLP-1的作用时间，从而提高血液中内源性GLP-1和GIP的浓度，并zui终改善血糖控制。2013年抗糖尿病治疗药物销售额达到了469亿美元的市场规模 ，其中DPP-4抑制剂销售市场达到93.88亿美元，同比上一年增长了10.24%，是快速发展的一类药物。
深圳远扬化学可提供奥格列汀申报所用全套杂质， 随货附CoA证书，HNMR，MS，HPLC图谱，纯度符合申报要求，欢迎我司（何 ；phastandards； ）。请点击本页标题下方“进入该公司展台” 查看我司信息。
| MK-3102 | (2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-amine |
| MK-3102 Impurity 1 | tert-butyl ((2S,3S)-2-(2,5-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-yl)carbamate |
| MK-3102 Impurity 2 | tert-butyl ((2S,3R)-2-(2,5-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-yl)carbamate |
| MK-3102 Impurity 3 | tert-butyl ((2R,3R)-2-(2,5-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-yl)carbamate compound with tert-butyl ((2S,3S)-2-(2,5-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-yl)carbamate (1:1) |
| MK-3102 Impurity 4 | tert-butyl ((2R,3S)-2-(2,3-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-yl)carbamate |
| MK-3102 Impurity 5 | tert-butyl ((2R,3S)-2-(3,4-difluorophenyl)-5-oxotetrahydro-2H-pyran-3-yl)carbamate |
| MK-3102 Impurity 6 | 1-(methylsulfonyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole |
| MK-3102 Impurity 7 | S,5R)-2-(2,5-difluorophenyl)-5-(1-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(1H,4H,6H)-yl)tetrahydro-2H-pyran-3-amine |
| MK-3102 Impurity 8 | (2R,3S,5S)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-amine |
| MK-3102 Impurity 9 | (2S,3S,5S)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-amine |
| MK-3102 Impurity 10 | (2S,3S,5R)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-amine |
| MK-3102 Impurity 11 | (2S,3R,5S)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-amine |
| MK-3102 Impurity 12 | (2R,3R,5R)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-amine |
| MK-3102 Impurity 13 | (2S,3R,5R)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-amine |
| MK-3102 Impurity 14 | (2R,3R,5S)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-amine |
| MK-3102 Impurity 15 | (2R,3S,5R)-2-(2,5-difluorophenyl)-5-(pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-amine |
| MK-3102 Impurity 16 | (R)-5-((3R,5S,6R)-5-amino-6-(2,5-difluorophenyl)tetrahydro-2H-pyran-3-yl)-2-(methylsulfonyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole 5-oxide |
| MK-3102 Impurity 17 | N-((2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-yl)acetamide |
| MK-3102 Impurity 18 | N-((2R,3S,5R)-2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(2H,4H,6H)-yl)tetrahydro-2H-pyran-3-yl)benzenesulfonamide |
